Our dual GLP-1/GIP receptor agonist DA5-CH (KP405) has better neuroprotective effects in the MPTP mouse model of PD when directly compared to liraglutide [25, 28] and is furthermore more effective than exendin-4 in the 6-OHDA rat model of PD [63]. This evidence concerns the gene GCG and Parkinson disease.